Amengual, J. E. (2018). A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. American Society of Hematology (ASH).
Chicago Style (17th ed.) CitationAmengual, J. E. A Phase 1 Study of Romidepsin and Pralatrexate Reveals Marked Activity in Relapsed and Refractory T-cell Lymphoma. American Society of Hematology (ASH), 2018.
MLA (9th ed.) CitationAmengual, J. E. A Phase 1 Study of Romidepsin and Pralatrexate Reveals Marked Activity in Relapsed and Refractory T-cell Lymphoma. American Society of Hematology (ASH), 2018.
Warning: These citations may not always be 100% accurate.